Penn Medicine Provider
Medical Oncology
John A. Kosteva, MD
4.9
(748)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Valley Forge
Make an appointmentCall 800-789-7366

About me

  • Clinical Associate Professor of Medicine (Hematology-Oncology)

Education and training

  • Medical School: Temple University School of Medicine
  • Residency: Temple University Hospital
  • Fellowship: Fox Chase Cancer Center
  • Fellowship: Temple University Hospital

What my patients think about me

Average Rating
4.9

748 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
knows what he is doing
May 2025
5.0
5.0
great dr
May 2025
5.0
5.0
great experience
April 2025
5.0
5.0
very knowledgeable and informative

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Kosteva is a Penn Medicine physician.

Qualifications and experience

My research

Marmarelis ME, Scholes DG, McWilliams TL, Hwang WT, Kosteva J, Costello MR, Sun L, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy MA, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C. Electronic Medical Record–Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non–Small Cell Lung Cancer: Results From a Prospective Clinical Trial , JCO Oncol Pract. 2024 Jul 3:OP2400070. doi: 10.1200/OP.24.00070, 00: 2024,1-9

Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer. 2024 May;25(3):e161-e171. doi: 10.1016/j.cllc.2023.12.009. Epub 2023 Dec 22., 25(3): 2024,161-171

Aggarwal C, Marmarelis ME, Hwang WT, Scholes DG, McWilliams TL, Singh AP, Sun L, Kosteva J, Costello MR, Cohen RB, Langer CJ, Doucette A, Gabriel PN, Shulman LN, Rendle KA, Thompson JC, Bekelman JE, Carpenter EL. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer , JCO Precis Oncol. 2023 Jul;7:e2300191. doi: 10.1200/PO.23.00191., 7: 2023,e2300191

Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System , Clin Lung Cancer. 2023 Jul;24(5):474-482. doi: 10.1016/j.cllc.2023.03.013. Epub 2023 Apr 3.: 2023

Charu Aggarwal, Melina Elpi Marmarelis, Wei-Ting Hwang, Dylan G. Scholes, Tara McWilliams, Aditi Puri Singh, Lova Sun, John A. Kosteva, Michael Robert Costello, Roger B. Cohen, Corey J. Langer, Peter Edward Gabriel, Lawrence N. Shulman, Jeffrey C. Thompson, Erica L. Carpenter Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer , 10.1200/JCO.2022.40.16_suppl.9022 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 9022-9022., 40(16): 2022

Nikhil Yegya-Raman, Cole Friedes, Lova Sun, Melina Elpi Marmarelis, William C. Levin, Keith A. Cengel, Brian Lally, Christopher Davella, John A. Kosteva, Aditi Puri Singh, Roger B. Cohen, Charu Aggarwal, Christine Ciunci, Abigail T. Berman, Corey J. Langer, Steven J. Feigenberg Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system , 10.1200/JCO.2022.40.16_suppl.8523 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 8523-8523., 40(16): 2022

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.: 2017

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. , Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.: 2016

Kosteva J, Langer C The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. , Current Opinion in Oncology, 20(2): 2008,155-161

Kosteva J, Langer C Skeletal metastases: Optimal management in 2007. , Supportive Care in Cancer Therapy: 2008